Skip to main content
SpringerLink
Log in

Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation

  • Original Article―Liver, Pancreas, and Biliary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

The relationship between liver fibrosis and inflammation and Mac-2-binding protein glycosylation isomer (M2BPGi) in patients with chronic liver disease (CLD) other than hepatitis C remains uncertain, owing to the limitations of qualitative methods. Here, we evaluated the influence of liver fibrosis and inflammation on quantitative M2BPGi (M2BPGi-Qt) in CLD, considering each etiology.

Methods

We recruited 1373 patients with CLD. To evaluate the influence of liver fibrosis and inflammation on M2BPGi-Qt levels, we assessed M2BPGi-Qt levels at each fibrosis and activity stage within different etiologies of CLD based on pathological findings. Subsequently, we evaluated if the accuracy of fibrosis staging based on M2BPGi-Qt could be improved by considering the influence of liver inflammation.

Results

In patients with viral hepatitis, non-alcoholic fatty liver disease, and primary biliary cholangitis, the median M2BPGi-Qt levels increased liver fibrosis progression. Median M2BPGi-Qt levels were not associated with the degree of fibrosis in patients with autoimmune hepatitis (AIH). Median M2BPGi-Qt levels increased with the progression of liver activity in all etiologies. A significant difference was found at each stage in AIH. Considering the liver inflammation, we established an algorithm, M2BPGi-Qt, to determine the alanine aminotransferase-to-platelet ratio (MAP-R) in liver cirrhosis (LC). The area under the receiver operating characteristic curve (AUC) of MAP-R was higher than that of the M2BPGi-Qt for detecting LC (AUC MAP-R = 0.759 and M2BPGi-Qt = 0.700, p < 0.001).

Conclusions

The quantitative measurement system for M2BPGi depends on liver fibrosis and inflammation, regardless of etiology. Liver inflammation complicates the interpretation of M2BPGi-Qt results when assessing the fibrosis stage.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Ginès P, Krag A, Abraldes JG, Solà E, et al. Liver cirrhosis. Lancet. 2021;398:1359–76.

    Article  PubMed  Google Scholar 

  2. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology. 2009;49(3):1017–44.

    Article  PubMed  Google Scholar 

  3. Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68:305–15.

    Article  CAS  PubMed  Google Scholar 

  4. Toshima T, Shirabe K, Ikegami T, et al. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP), for assessing liver fibrosis. J Gastroenterol. 2015;50:76–84.

    Article  CAS  PubMed  Google Scholar 

  5. Nah EH, Cho S, Kim S, et al. Diagnostic performance of Mac-2 binding protein glycosylation isomer (M2BPGi) in screening liver fibrosis in health checkups. J Clin Lab Anal. 2020;34: e23316.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Morio K, Imamura M, Daijo K, et al. Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury. J Gastroenterol. 2017;52:1252–7.

    Article  CAS  PubMed  Google Scholar 

  7. Shirabe K, Bekki Y, Gantumur D, et al. Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: More than a biomarker of liver fibrosis. J Gastroenterol. 2018;53:819–26.

    Article  CAS  PubMed  Google Scholar 

  8. Abe M, Miyake T, Kuno A, et al. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol. 2015;50:776–84.

    Article  CAS  PubMed  Google Scholar 

  9. Nakagawa M, Nawa N, Takeichi E, et al. Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs. J Gastroenterol. 2020;55:990–9.

    Article  CAS  PubMed  Google Scholar 

  10. Narimatsu H. Development of M2BPGi: a novel fibrosis serum glyco-biomarker for chronic hepatitis/cirrhosis diagnostics. Expert Rev Proteomics. 2015;12(6):683–93.

    Article  CAS  PubMed  Google Scholar 

  11. Uojima H, Nakabayashi K, Yamasaki K, et al. New chemiluminescent enzyme immunoassay for quantitative measurement of Mac-2 binding protein glycosylation isomer in chronic liver disease. J Gastroenterol. 2023;58:1252–60.

    Article  CAS  PubMed  Google Scholar 

  12. Ichida F, Tsuji T, Omata M, et al. New Inuyama classification; new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun. 1996;6:112–9.

    Article  Google Scholar 

  13. Bedossa P, Poitou C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56:1751–9.

    Article  PubMed  Google Scholar 

  14. Nakanuma Y, Saito K, Unoura M. Semiquantitative assessment of cholestasis and lymphocytic piecemeal necrosis in primary biliary cirrhosis: a histologic and immunohistochemical study. J Clin Gastroenterol. 1990;12:357–62.

    Article  CAS  PubMed  Google Scholar 

  15. Kimura Y, Taura K, Hai Nam N, et al. Utility of Mac-2 binding protein glycosylation isomer to evaluate graft status after liver transplantation. Liver Transpl. 2021;27:403–15.

    Article  PubMed  Google Scholar 

  16. Nishikawa H, Enomoto H, Iwata Y, et al. Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level and high-sensitivity C-reactive protein concentration in autoimmune hepatitis. Hepatol Res. 2016;46:613–21.

    Article  CAS  PubMed  Google Scholar 

  17. Sucher E, Sucher R, Gradistanac T, et al. Autoimmune hepatitis-immunologically triggered liver pathogenesis-diagnostic and therapeutic strategies. J Immunol Res. 2019;2019:9437043.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Bekki Y, Yoshizumi T, Shimoda S, et al. Hepatic stellate cells secreting WFA+ -M2BP: its role in biological interactions with Kupffer cells. J Gastroenterol Hepatol. 2017;32:1387–93.

    Article  CAS  PubMed  Google Scholar 

  19. Ishii A, Nishikawa H, Enomoto H, et al. Clinical implications of serum Wisteria floribunda agglutinin-positive Mac-2-binding protein in treatment-naïve chronic hepatitis B. Hepatol Res. 2017;47:204–15.

    Article  CAS  PubMed  Google Scholar 

  20. Higashioka M, Hirakawa Y, Hata J, et al. Serum Mac-2 binding protein glycosylation isomer concentrations are associated with incidence of type 2 diabetes. J Clin Endocrinol Metab. 2023;108:e425–33.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Singh T, Allende DS, McCullough AJ. Assessing liver fibrosis without biopsy in patients with HCV or NAFLD. Cleve Clin J Med. 2019;86:179–86.

    Article  PubMed  Google Scholar 

  22. Kjaergaard M, Lindvig KP, Thorhauge KH, et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol. 2023;79:277–86.

    Article  CAS  PubMed  Google Scholar 

  23. Thomas MR, Storey RF. The role of platelets in inflammation. Thromb Haemost. 2015;114:449–58.

    Article  PubMed  Google Scholar 

  24. Itakura J, Kurosaki M, Setoyama H, et al. Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis. J Gastroenterol. 2021;56:470–8.

    Article  CAS  PubMed  Google Scholar 

  25. Demler OV, Pencina MJ, Cook NR, et al. Asymptotic distribution of ∆AUC, NRIs, and IDI based on theory of U-statistics. Stat Med. 2017;36:3334–60.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Zhang D, Cao Y, Sun Y, et al. Radiomics nomograms based on R2* mapping and clinical biomarkers for staging of liver fibrosis in patients with chronic hepatitis B: a single-center retrospective study. Eur Radiol. 2023;33:1653–67.

    Article  PubMed  Google Scholar 

  27. Noro E, Matsuda A, Kyoutou T, et al. N-glycan structures of Wisteria floribunda agglutinin-positive Mac2 binding protein in the serum of patients with liver fibrosis. Glycobiology. 2021;31:1268–78.

    Article  CAS  PubMed  Google Scholar 

  28. Nagaoka K, Tanaka M, Tanaka Y. Mac-2 binding protein and its glycan isomer: where does it come from? Where is it going? Hepatol Res. 2021;51:1026–8.

    Article  CAS  PubMed  Google Scholar 

  29. Gantumur D, Harimoto N, Muranushi R, et al. Hepatic stellate cell as a Mac-2-binding protein-producing cell in patients with liver fibrosis. Hepatol Res. 2021;51:1058–63.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank STATISTA Corporation for assisting with the statistical analyses in this study.

This study was supported by Sysmex Corporation.

Funding

This study was supported by Sysmex Corporation.

Author information

Authors and Affiliations

  1. Genome Medical Sciences Project, Research Institute, National Center for Global Health and Medicine, 1-7-1, Kohnodai, Ichikawa, Chiba, 272-8516, Japan

    Haruki Uojima & Masashi Mizokami

  2. Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan

    Haruki Uojima, Hisashi Hidaka & Chika Kusano

  3. Clinical Research Center, National Hospital Organization, Nagasaki Medical Center, Ōmura, Japan

    Kazumi Yamasaki & Hiroshi Yatsuhashi

  4. Department of Viral Pathogenesis and Controls, Research Institute, National Center for Global Health and Medicine, Ichikawa, Chiba, Japan

    Masaya Sugiyama

  5. Department of Pathology, Junshin Gakuen University, Fukuoka, Japan

    Masayoshi Kage

  6. Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Gunma, Japan

    Norihiro Ishii & Ken Shirabe

  7. Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Yushima, Bunkyo-Ku, Tokyo, Japan

    Miyako Murakawa & Yasuhiro Asahina

  8. Department of Liver Disease Control, Tokyo Medical and Dental University, Yushima, Bunkyo-Ku, Tokyo, Japan

    Yasuhiro Asahina

  9. Division of Hepatobiliary and Pancreatic Disease, Department of Gastroenterology, Hyogo Medical University, Nishinomiya, Hyogo, Japan

    Takashi Nishimura & Hiroko Iijima

  10. Department of Gastroenterology, Aichi Medical University, Nagakute, Aichi, Japan

    Kazumasa Sakamoto & Kiyoaki Ito

  11. Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Asahi-Machi, Kurume, Fukuoka, Japan

    Keisuke Amano & Takumi Kawaguchi

  12. Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino, Tokyo, Japan

    Nobuharu Tamaki & Masayuki Kurosaki

  13. Department of Gastroenterology and Metabolism, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan

    Takanori Suzuki & Kentaro Matsuura

  14. Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan

    Akinobu Taketomi

  15. Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Asahi, Matsumoto, Japan

    Satoru Joshita & Takeji Umemura

  16. Department of Hepatology and Pancreatology, Kawasaki Medical School, Aichi, Japan

    Sohji Nishina & Keisuke Hino

  17. Digestive Disease Center, Shunan Memorial Hospital, Yamaguchi, Japan

    Keisuke Hino

  18. Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan

    Hidenori Toyoda

Authors
  1. Haruki Uojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazumi Yamasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masaya Sugiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masayoshi Kage
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Norihiro Ishii
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ken Shirabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hisashi Hidaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chika Kusano
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Miyako Murakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yasuhiro Asahina
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Takashi Nishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hiroko Iijima
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Kazumasa Sakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Kiyoaki Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Keisuke Amano
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Takumi Kawaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Nobuharu Tamaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Masayuki Kurosaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Takanori Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Kentaro Matsuura
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Akinobu Taketomi
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Satoru Joshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Takeji Umemura
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Sohji Nishina
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Keisuke Hino
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. Hidenori Toyoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. Hiroshi Yatsuhashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. Masashi Mizokami
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HU, KY, NI, MM, TK, TS, SJ, and HT collected and analyzed the data; HU and MM drafted the manuscript; KS designed and supervised the study; KY, TK, and HY offered technical or material support. All authors have read and approved the final version of the manuscript.

Corresponding author

Correspondence to Haruki Uojima.

Ethics declarations

Conflict of interest

Takeji Umemura received lecture fees from AbbVie GK and Gilead Sciences and research grants from AbbVie GK, Eisai Co., Otsuka Pharmaceutical Co., and Tosoh Co. Masayuki Kurosaki received lecture fees from AbbVie, Eisai, Chugai, AstraZeneca, Lilly, and Takeda Co. Masashi Mizokami received lecture fees from Sysmec Co. Yasuhiro Asahina received lecture fees from Fujirebi Inc. and Abbott Japan LLC. Takumi Kawaguchi received lecture fees from Taisho Pharmaceutical Co., Kowa Company, Otsuka Pharmaceutical Co., Eisai Co., Janssen Pharmaceutical K.K., AbbVie GK., ASKA Pharmaceutical Co., and EA Pharma Co., and a research grant from Eisai Co., Ltd.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 259 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Uojima, H., Yamasaki, K., Sugiyama, M. et al. Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation. J Gastroenterol (2024). https://doi.org/10.1007/s00535-024-02100-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00535-024-02100-3

Keywords

Search

Navigation